^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) + capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study)
Published date:
11/23/2021
Excerpt:
The study of the population included metastatic human epidermal growth factor receptor 2 (HER2) negative gastric adenocarcinoma…. The 12-month survival rate was 46.7%, and the median survival was 11.5 months (interquartile range [IQR]: 15.3-6.9)….Treatment included six 21-day cycles of cisplatin (80 mg/m2 IV, day 1) plus capecitabine (1000 mg/m2 PO BD, days 1-14) plus IP paclitaxel (days 1 and 8)....IP paclitaxel is safe in combination with cisplatin and capecitabine and the recommended phase-2 dose is 30 mg/m2.
DOI:
10.1111/ajco.13659
